Global Human Low-Pass Whole Genome Sequencing Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Human Low-Pass Whole Genome Sequencing Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Human low-pass whole-genome sequencing is generally defined as sequencing the genome. Combined with genotype imputation, it provides an alternative to genotyping arrays for trait mapping and polygenic score calculations.
Human Low-Pass Whole Genome Sequencing report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Human Low-Pass Whole Genome Sequencing market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Medical and Scientific Research are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Human Low-Pass Whole Genome Sequencing industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, Human Low-Pass Whole Genome Sequencing key companies include BGI, Breda Genetics, Azenta Life Sciences, Thermo Fisher Scientific, Psomagen, Healgen Scientific, Agilent Technologies, Macrogen and Veritas Genetics, etc. BGI, Breda Genetics, Azenta Life Sciences are top 3 players and held % share in total in 2022.
Human Low-Pass Whole Genome Sequencing can be divided into Large Human Low-Through Whole Genome Sequencing (> 5 Mb) and Small Human Low-Through Whole Genome Sequencing (≤ 5 Mb), etc. Large Human Low-Through Whole Genome Sequencing (> 5 Mb) is the mainstream product in the market, accounting for % share globally in 2022.
Human Low-Pass Whole Genome Sequencing is widely used in various fields, such as Medical, Scientific Research and Others,, etc. Medical provides greatest supports to the Human Low-Pass Whole Genome Sequencing industry development. In 2022, global % share of Human Low-Pass Whole Genome Sequencing went into Medical filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Human Low-Pass Whole Genome Sequencing market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
BGI
Breda Genetics
Azenta Life Sciences
Thermo Fisher Scientific
Psomagen
Healgen Scientific
Agilent Technologies
Macrogen
Veritas Genetics
Centogene
Nebula Genomics
CD Genomics
Segment by Type
Large Human Low-Through Whole Genome Sequencing (> 5 Mb)
Small Human Low-Through Whole Genome Sequencing (≤ 5 Mb)
Medical
Scientific Research
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Human Low-Pass Whole Genome Sequencing market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Human Low-Pass Whole Genome Sequencing introduction, etc. Human Low-Pass Whole Genome Sequencing Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Human Low-Pass Whole Genome Sequencing market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Human Low-Pass Whole Genome Sequencing report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Human Low-Pass Whole Genome Sequencing market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Medical and Scientific Research are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Human Low-Pass Whole Genome Sequencing industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, Human Low-Pass Whole Genome Sequencing key companies include BGI, Breda Genetics, Azenta Life Sciences, Thermo Fisher Scientific, Psomagen, Healgen Scientific, Agilent Technologies, Macrogen and Veritas Genetics, etc. BGI, Breda Genetics, Azenta Life Sciences are top 3 players and held % share in total in 2022.
Human Low-Pass Whole Genome Sequencing can be divided into Large Human Low-Through Whole Genome Sequencing (> 5 Mb) and Small Human Low-Through Whole Genome Sequencing (≤ 5 Mb), etc. Large Human Low-Through Whole Genome Sequencing (> 5 Mb) is the mainstream product in the market, accounting for % share globally in 2022.
Human Low-Pass Whole Genome Sequencing is widely used in various fields, such as Medical, Scientific Research and Others,, etc. Medical provides greatest supports to the Human Low-Pass Whole Genome Sequencing industry development. In 2022, global % share of Human Low-Pass Whole Genome Sequencing went into Medical filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Human Low-Pass Whole Genome Sequencing market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
BGI
Breda Genetics
Azenta Life Sciences
Thermo Fisher Scientific
Psomagen
Healgen Scientific
Agilent Technologies
Macrogen
Veritas Genetics
Centogene
Nebula Genomics
CD Genomics
Segment by Type
Large Human Low-Through Whole Genome Sequencing (> 5 Mb)
Small Human Low-Through Whole Genome Sequencing (≤ 5 Mb)
Segment by Application
Medical
Scientific Research
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Human Low-Pass Whole Genome Sequencing market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Human Low-Pass Whole Genome Sequencing introduction, etc. Human Low-Pass Whole Genome Sequencing Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Human Low-Pass Whole Genome Sequencing market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.